COLUMN GROUP III-A, LP
CIK 1668085 · last filed 2026-01-15
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
TNYA price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SUITE 500
SAN FRANCISCO, CA 94158
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Surrozen, Inc./DE (SRZNW) Delisted | 10%+ Owner | 996,502 | $0.00 | $1.5K | $2.50M | 1 | 2026-01-15 |
| NGM BIOPHARMACEUTICALS INC (NGM) Delisted | 10%+ Owner | 11,203,333 | $1.54 | $17.25M | $47.33M | 10 | 2023-01-17 |
| TNYA | 10%+ Owner | 4,414,720 | $0.41 | $1.80M | $150.00M | 1 | 2022-11-23 |
| RVMD | 10%+ Owner | 7,977,384 | $183.90 | $1.47B | $0 | 1 | 2020-02-18 |
Recent Filings · Page 2 of 2
17 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2020-04-07 | NGM BIOPHARMACEUTICALS INC (NGM) Delisted | Buy (P) | +553,260 | $7.84M | EDGAR |
| 2020-04-02 | NGM BIOPHARMACEUTICALS INC (NGM) Delisted | Buy (P) | +1,003,936 | $12.44M | EDGAR |
| 2020-03-06 | NGM BIOPHARMACEUTICALS INC (NGM) Delisted | Buy (P) | +33,228 | $598.1K | EDGAR |
| 2020-02-18 | RVMD | Conv (C) | +79,773,840 | $0 | EDGAR |
| 2020-02-10 | NGM BIOPHARMACEUTICALS INC (NGM) Delisted | Buy (P) | +179,600 | $2.87M | EDGAR |
| 2019-10-24 | NGM BIOPHARMACEUTICALS INC (NGM) Delisted | Buy (P) | +17,548 | $209.4K | EDGAR |
| 2019-10-11 | NGM BIOPHARMACEUTICALS INC (NGM) Delisted | Buy (P) | +212,688 | $2.22M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.